Journal article
Night-time sleep in Parkinson's disease - the potential use of Parkinson's KinetiGraph: A prospective comparative study
L Klingelhoefer, A Rizos, A Sauerbier, S Mcgregor, P Martinez-Martin, H Reichmann, M Horne, KR Chaudhuri
European Journal of Neurology | WILEY | Published : 2016
DOI: 10.1111/ene.13015
Abstract
© 2016 European Federation of Neurological Societies.Background and purpose: Night-time sleep disturbances are important non-motor symptoms and key determinants of health-related quality of life (HRQoL) in patients with Parkinson's disease (PD). The Parkinson's KinetiGraph (PKG) can be used as an objective measure of different motor states and periods of immobility may reflect episodes of sleep. Our aim was to evaluate whether PKG can be used as an objective marker of disturbed night-time sleep in PD. Methods: In this prospective comparative study, data from PKG recordings over six consecutive 24 h periods are compared with Hauser diaries and scales focusing on motor state, sleep and HRQoL i..
View full abstractGrants
Funding Acknowledgements
Lisa Klingelhoefer reports grants from PDNMG and COST European Dystonia Research Network, outside the submitted work. Alexandra Rizos and Anna Sauerbier: none. Sarah McGregor reports that GKC has provided a travel grant in 2014 to attend the Movement Disorder Society Conference in Stockholm. GKC have provided an open research grant to the Florey Neuroscience Institute which in conjunction with other research grants is paid to St Vincent's Hospital Melbourne. Pablo Martinez-Martin reports personal fees from TEVA, Lundbeck, Italfarmaco, AbbVie, Movement Disorder Society, National School of Public Health (ISCIII), Complutense University, UCB and Universidad Politecnica de Madrid (summer course 2015), Editorial Viguera, Mundipharma, grants from Fondo de Investigacion Sanitaria (FIS-ISCIII), IMSERSO (Ministry of Health PSI), Parkinson's UK, Parkinson's Disease Non-Motor Group, Reina Sofia Foundation, all outside the submitted work. Heinz Reichmann has served on advisory boards, given lectures and received research grants from Abbott, Abbvie, Bayer Health Care, Boehringer/Ingelheim, Brittania Pharmaceuticals, Cephalon, Desitin, GlaxoSmithKline, Lundbeck, Medtronic, MerckSerono, Novartis, Orion Pharma, Pfizer, Teva Pharmaceutical Industries, UCB, Valeant Pharmaceutical International, Zambon and Global Kinetics Corporation, all outside the submitted work. Malcolm Horne is a manufacturer of the PKG and holds patents covering the PKG. K Ray Chaudhuri reports grants and personal fees from GSK Pharmaceuticals, Britannia Pharmaceuticals, AbbVie, UCB, Mundipharma, Neuronova, Boehringer Ingelheim, Global Kinetics Corporation, grants from Parkinson's UK, NIHR, PDNMG, EU, outside the submitted work.